Fierce Biotech February 22, 2024
In the wake of a full-year earnings sheet that showed an 8% year-over-year drop in revenues and a major slump in operating income that sent its net earnings into the red, QuidelOrtho is making some changes at the top.
The company’s board of directors has opted to terminate its chief executive, Douglas Bryant, effective Wednesday, per a QuidelOrtho announcement that morning. In addition to losing his roles as president and CEO, Bryant has also stepped down from the board.
Bryant had led the company for almost exactly 15 years, starting at Quidel in 2009 and overseeing operations through its $6 billion merger with Ortho Clinical Diagnostics, which was completed in 2022. Prior to joining Quidel, he was CEO of Luminex...
Today's Sponsors
Today's Sponsor